扶正抑瘤汤联合索拉非尼对晚期肝癌患者血清胰岛素样生长因子Ⅱ、CD44的影响分析

Effect of Fuzhengyiliu Soup Combined with Sorafenib on Serum Insulin-like Growth Factor Ⅱ and CD44 in HCC Patients

目的探究扶正抑瘤汤联合索拉非尼对肝癌患者血清胰岛素样生长因子Ⅱ、CD44的影响。方法将150例晚期肝癌患者根据治疗方法的不同,按随机抽样的方法分为实验组和对照组。对照组仅给予甲苯磺酸索拉非尼片;实验组在服用甲苯磺酸索拉非尼片的同时,给予扶正抑瘤汤。测定所有患者治疗前的CD44阳性率及血清胰岛素样生长因子Ⅱ的含量,并且记录每个疗程之后的各组数据,连续测量3个疗程,进行比较。结果治疗前2组患者的CD44及血清胰岛素样生长因子Ⅱ水平差异无统计学意义,前2个疗程2组治疗效果不明显,差异亦无统计学意义;经过3个疗程之后,2组患者CD44及血清胰岛素样生长因子Ⅱ均明显下降,且2组差异有统计学意义。结论扶正抑瘤汤联合索拉非尼治疗晚期肝癌疗效明显,血清胰岛素样生长因子Ⅱ、CD44有明显下降,值得临床推广。

Objective To explore the effect of fuzhengyiliu soup combined with sorafenib on serum insulin-like growth factor Ⅱand CD44 in hepatocellular carcinoma( HCC) patients. Methods 150 cases of HCC were randomly divided into the control group and the treatment group,each with 75 cases. The control group received sorafenib,and the treatment group received Fuzhengyiliu soup combined with sorafenib. After 3 courses of treatments,serum insulin-like growth factor Ⅱand CD44 of the 2groups were assessed. Results CD44 and serum insulin-like growth factor Ⅱ of the 2 groups before treatment had no statistically significant difference. After 2 courses of treatment,the treatment effects of the 2 groups had no statistically significant difference;After 3 courses of treatment,CD44 and serum insulin-like growth factor Ⅱ of the 2 groups were significantly lower,and the difference was statistically significant. Conclusion Fuzhengyiliu soup combined with sorafenib for HCC is effective,CD44 and serum insulin-like growth factor Ⅱsignificantly reduced,and it is worthy of clinical promotion.